rewrite this title An Exciting Diagnostics IPO Nobody Is Talking About – Nanalyze

The ongoing U.S. government shutdown means that private companies wanting to go public are facing delays. While the IPO market may be frozen, that’s not stopping some from continuing to announce their intentions to go public. One such name is BillionToOne which is flying under the media’s radar despite some impressive growth, potential for profitability, and a lean company culture. And let’s be honest. If the company was named “BillionToOne AI,” it would probably be getting a lot more attention.

A Billion to One

BillionToOne has developed a molecular counting platform that can help quantify nearly undetectable DNA changes. It all starts with cell-free DNA or cfDNA which refers to small fragments of DNA circulating outside of cells in body fluids like blood or urine. It’s a key component of liquid biopsies and has important applications in areas like prenatal screening for genetic conditions, cancer detection and monitoring, and assessing organ transplant rejection. And now the company’s odd name makes a lot more sense:

The cornerstone of our platform is its ability to resolve and quantify individual DNA molecules with absolute precision. This single-molecule resolution provides extraordinary visibility into the biological signals present in a sample, even when the target DNA represents just one molecule among billions.

BillionToOne can create differentiated prenatal and oncology products with 10 times greater precision versus other available tests. The granularity at which they can perform diagnostic tests also unlocks functional improvements for non-invasive prenatal screening and liquid biopsies. This poses a formidable threat to companies like Natera (NTRA) and